SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q1 FY23 results · Apr–Jun 2022
SMS Pharmaceuticals reported revenue from operations of ₹64.39 crore (down 60.5% from Q1 FY22) and net loss of ₹12.77 crore for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 64.39 | 163.00 | −60.5% | 60.92 | +5.7% |
| Other income | 0.80 | 1.29 | −37.7% | 0.43 | +87.9% |
| Total income | 65.19 | 164.29 | −60.3% | 61.35 | +6.3% |
| Profit before share of associates & JVs and tax | (12.79) | 32.77 | Turned loss | (16.33) | Loss narrowed |
| Share of profit/(loss) of associates & JVs | (2.58) | 0.00 | (2.73) | ||
| Net profit for the period | (12.77) | 23.20 | Turned loss | 6.17 | Turned loss |
| EPS, basic (₹) | (1.51) | 2.74 | Turned loss | 0.73 | Turned loss |
| Net margin (%) | -19.8 | 14.2 | 10.1 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 64.39 | 163.00 | −60.5% | 60.92 | +5.7% |
| Other income | 0.80 | 1.29 | −37.7% | 0.43 | +87.9% |
| Total income | 65.19 | 164.29 | −60.3% | 61.35 | +6.3% |
| Profit before tax | (12.41) | 32.77 | Turned loss | (16.17) | Loss narrowed |
| Net profit for the period | (9.81) | 23.20 | Turned loss | 9.06 | Turned loss |
| EPS, basic (₹) | (1.16) | 2.74 | Turned loss | 1.07 | Turned loss |
| Net margin (%) | -15.2 | 14.2 | 14.9 |
Consolidated
- Filed with BSE
- 06 Sep 2022, 15:18 IST
- Board meeting
- 13 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Sep 2022, 15:18 IST
- Board meeting
- 13 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE